Sensei Biotherapeutics Announces Board Reconstitution Updates and Appointment Delays

On May 22, 2026, Sensei Biotherapeutics, Inc. announced updates regarding its Board of Directors reconstitution ahead of the 2026 Annual Meeting of Stockholders scheduled for June 10, 2026. Karen Vousden, Ph.D., has requested a delay in her appointment to the Board for personal reasons; the Board now intends to consider her appointment in the third or fourth quarter of 2026. Additionally, provided that the required stockholder matters are approved at the upcoming meeting, the Board plans to appoint Bob Holmen as chair of the Nominating and Corporate Governance Committee, effective June 12, 2026. Concurrent with these changes, the Board has approved a reduction in its size to five directors, effective June 12, 2026. These updates supplement the information previously provided in the company's definitive proxy statement filed on April 27, 2026. The company noted that these forward-looking plans are subject to stockholder approval and other standard corporate contingencies.